Replication FailureOpen accessMedicine· cited by 9

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study

Gavin Giovannoni; Gavin Giovannoni; Laura M. Airas; Riley M. Bove; Gary R Cutter; Maciej Czarnecki; Jelena S. Drulovic; JC Hobart · 2026 · The Lancet

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

BACKGROUND: The ORATORIO trial showed that ocrelizumab reduced the risk of disability progression versus placebo in patients with primary progressive multiple sclerosis (PPMS). We aimed to elucidate the effect of ocrelizumab in older and more disabled patients with PPMS, particularly regarding hand function preservation. METHODS: ORATORIO-HAND was a multicentre, double-blind, randomised, placebo-controlled, phase 3b study with 138 sites across 22 countries. Patients with PPMS aged 18-65 years and Expanded Disability Status Scale (EDSS) score of 3·0-8·0 were randomly assigned 1:1 to intravenous

Abstract by Gavin Giovannoni; Gavin Giovannoni; Laura M. Airas; Riley M. Bove; Gary R Cutter; Maciej Czarnecki; Jelena S. Drulovic; JC Hobart, The Lancet (2026) — licensed CC BY 4.0.

Read the full paper (open access)